Cargando…

Discontinuation of antiepileptic drugs in adults with epilepsy

Patients with epilepsy who have been free of seizures for at least two years may be able to stop their antiepileptic drugs. Discontinuation may be considered after an individualised harm–benefit assessment and consultation with a neurologist is recommended. It is paramount to discuss with patients w...

Descripción completa

Detalles Bibliográficos
Autor principal: Laue-Gizzi, Hanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: NPS MedicineWise 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075746/
https://www.ncbi.nlm.nih.gov/pubmed/33911333
http://dx.doi.org/10.18773/austprescr.2021.005
_version_ 1783684580212998144
author Laue-Gizzi, Hanka
author_facet Laue-Gizzi, Hanka
author_sort Laue-Gizzi, Hanka
collection PubMed
description Patients with epilepsy who have been free of seizures for at least two years may be able to stop their antiepileptic drugs. Discontinuation may be considered after an individualised harm–benefit assessment and consultation with a neurologist is recommended. It is paramount to discuss with patients whether the risk of seizure recurrence is worth the benefit of stopping the antiepileptic drug. The risk of seizure recurrence after antiepileptic drugs are discontinued depends on the epilepsy syndrome and a number of other risk factors. Approximately 30–50% of patients will relapse. If seizures recur, the majority of patients regain seizure control when treatment is resumed. However up to 20% do not achieve immediate remission.
format Online
Article
Text
id pubmed-8075746
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher NPS MedicineWise
record_format MEDLINE/PubMed
spelling pubmed-80757462021-04-27 Discontinuation of antiepileptic drugs in adults with epilepsy Laue-Gizzi, Hanka Aust Prescr Aricle Patients with epilepsy who have been free of seizures for at least two years may be able to stop their antiepileptic drugs. Discontinuation may be considered after an individualised harm–benefit assessment and consultation with a neurologist is recommended. It is paramount to discuss with patients whether the risk of seizure recurrence is worth the benefit of stopping the antiepileptic drug. The risk of seizure recurrence after antiepileptic drugs are discontinued depends on the epilepsy syndrome and a number of other risk factors. Approximately 30–50% of patients will relapse. If seizures recur, the majority of patients regain seizure control when treatment is resumed. However up to 20% do not achieve immediate remission. NPS MedicineWise 2021-04-01 2021-04 /pmc/articles/PMC8075746/ /pubmed/33911333 http://dx.doi.org/10.18773/austprescr.2021.005 Text en (c) NPS MedicineWise https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.
spellingShingle Aricle
Laue-Gizzi, Hanka
Discontinuation of antiepileptic drugs in adults with epilepsy
title Discontinuation of antiepileptic drugs in adults with epilepsy
title_full Discontinuation of antiepileptic drugs in adults with epilepsy
title_fullStr Discontinuation of antiepileptic drugs in adults with epilepsy
title_full_unstemmed Discontinuation of antiepileptic drugs in adults with epilepsy
title_short Discontinuation of antiepileptic drugs in adults with epilepsy
title_sort discontinuation of antiepileptic drugs in adults with epilepsy
topic Aricle
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8075746/
https://www.ncbi.nlm.nih.gov/pubmed/33911333
http://dx.doi.org/10.18773/austprescr.2021.005
work_keys_str_mv AT lauegizzihanka discontinuationofantiepilepticdrugsinadultswithepilepsy